Instituut Verbeeten

What Instituut Verbeeten does

Instituut Verbeeten is a Dutch specialized radiotherapy institute founded in 1953 and operated as Stichting Dr. Bernard Verbeeten Instituut, an ANBI-registered public benefit foundation headquartered in Tilburg, Netherlands. The institute provides external beam radiotherapy, internal radiotherapy (brachytherapy), stereotactic radiotherapy, hyperthermia, and adaptive radiotherapy to cancer patients referred from general and academic hospitals across the West to Northeast Brabant region. It operates three physical locations — Tilburg (headquarters, Brugstraat 10), Breda (Hogeschoollaan 4), and Den Bosch (Deutersestraat 2b) — and treats approximately 4,500 cancer patients annually with a workforce of around 225 staff. Patient-reported outcomes include a satisfaction score of 9.1/10, an NPS of 88, and ~90% recommendation rate; referrer satisfaction is reported at 100%. Nuclear medicine services were transferred to Elisabeth-TweeSteden Ziekenhuis (ETZ) on 12 April 2025, narrowing the institute to its core radiotherapy franchise.

Name

Instituut Verbeeten

Legal name

Stichting Dr. Bernard Verbeeten Instituut

Website

https://verbeeten.nl

Company type

Private

Founded year

1953

Operating status

Operating

Headcount range

101–250 employees

Short description

Instituut Verbeeten is a Dutch ANBI-registered radiotherapy foundation operating three sites in Tilburg, Breda, and Den Bosch, delivering external beam, internal, stereotactic, and adaptive radiotherapy to approximately 4,500 cancer patients annually across the Brabant region, reimbursed under Dutch basic health insurance.

Ownership category

akta.pro rank

Product category

Radiotherapy Services

NAICS

Other Ambulatory Health Care Services (6219), Diagnostic Imaging Centers (621512)

SIC

Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Radiation Oncology (HLAKAFAC)

akta.pro secondary industries

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology) (EUAKAIAD)

Keywords

• Radiotherapy services
• Cancer treatment center
• Radiation oncology
• Brachytherapy treatments
• Adaptive radiotherapy

Headquarters

HQ city

Tilburg

HQ country

Netherlands

HQ region

Europe

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Others

Revenue model

1. Radiotherapy Treatment Services: Radiotherapy treatments are reimbursed from the basic health insurance package under Dutch healthcare law. Patients are responsible for their deductible (eigen risico) and sometimes a personal contribution. The institution bills health insurers directly for treatments and follow-up care.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Instituut Verbeeten is a specialized radiotherapy institute providing radiation therapy for cancer patients, including external beam radiotherapy, internal radiotherapy (brachytherapy), hyperthermia, stereotactic radiotherapy, and online adaptive radiotherapy. The institute operates three locations in the Netherlands (Tilburg, Breda, Den Bosch), treating approximately 4,500 cancer patients annually using advanced Varian linear accelerators and proprietary treatment planning software.

Product overview

Instituut Verbeeten is a radiotherapy institute offering comprehensive cancer treatment services. Their core offering is radiotherapy (radiation therapy) for cancer patients, including external radiotherapy, internal radiotherapy (brachytherapy), hyperthermia, and stereotactic treatments. They operate three locations in Tilburg, Breda, and Den Bosch, treating approximately 4,500 patients annually. Key technologies include the Ethos radiotherapy system with adaptive capabilities, HyperArc for brain metastases, and surface scanning (Identify) for tattoo-free positioning. They have developed in-house software tools including Eclipse Plug-Ins, Registratie Controle I-125, FTT OH Sheets, and VXP Correctie for treatment planning and quality assurance. The institute is equipped with advanced Varian Medical Systems linear accelerators across all locations.

Differentiator

Problem solved

Functional benefit

Brands

• Verbeeten Challenge: An annual sporting event where participants raise money for research and patient-friendly cancer treatments. Funds have supported technologies like surface scanning and HyperArc.
• Verwendag

Products and services

• External Beam Radiotherapy (Uitwendige bestraling)

Quantifiable outcome

• 4,500+ patients treated annually across three locations
• +8 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability5 records

Feature8 records

Partnerships

Nine partnerships are on record, tiered minor and core.

• Stichting de LotgenotenminorStrategic or Co-development Partner · 23 May 2026Annual joint organization of 'Verwendag' (Pampering Day) for families of cancer patients at Safaripark Beekse Bergen. The 14th edition in 2026 was attended by 59 families. Stichting de Lotgenoten consists of (former) cancer patients who organize activities and fundraising for peers.
• Elisabeth-TweeSteden Ziekenhuis (ETZ)coreStrategic or Co-development Partner · 12 April 2025Instituut Verbeeten transferred its nuclear medicine care to ETZ effective April 12, 2025. Approximately 95% of nuclear medicine patients were ETZ patients. The transfer enables ETZ to offer this care within its own organization, ensuring quality of nuclear care in the future. Research and treatment locations remain at Verbeeten's Brugstraat 10 address temporarily. ETZ contact: 013 – 221 04 70.
• TOON Centrum voor leven met en na kanker and ETZminorStrategic or Co-development Partner · 30 October 2023Joint organization of 'Longkanker, wat nu?' (Lung Cancer, What's Next?) public information evening for patients, relatives, and interested parties at ETZ auditorium. Part of ongoing collaboration to support cancer patients.
• Qualicor EuropeminorOthers · 1 May 2023Independent healthcare quality accreditation body that conducted a three-day audit and awarded Platinum accreditation status (2023-2027) based on Q-mentum Global standards.
• Tilburg University and ETZminorStrategic or Co-development Partner · 20 January 2023OPTIMIZE project researching two methods to support heart disease patients during cardiac imaging examinations, conducted jointly with Tilburg University and Elisabeth-TweeSteden Ziekenhuis.
• Medifit and ETZminorStrategic or Co-development Partner · 1 January 2022Joint research partnership between Instituut Verbeeten, Medifit (oncology physiotherapy), and ETZ on fitness, fatigue, and quality of life in patients with tumors in mouth, nose, or throat during and after treatment. Funded by €10,000 donation from Swim to Fight Cancer Tilburg.
• Radboud UMC and TU/e (Technical University Eindhoven)coreStrategic or Co-development Partner · 30 November 2021Research collaboration between Instituut Verbeeten, Radboud UMC, and TU/e on surface scanning technology for radiotherapy. Study published in Physics and Imaging in Radiation Oncology. Conducted by Janita Dekker, Teun Pieter van Wagenberg, Mariska de Smet, Marion Essers, Martijn Kusters, and Willy de Kruijf.
• Varian Medical SystemscoreTechnology or Integration · 20 September 2021Varian Medical Systems is the supplier of new radiotherapy linear accelerators (Ethos, HyperArc, HyperSight, Identify surface scanning). The partnership involves equipment supply, staff training, and ongoing technology collaboration to advance patient treatment quality.
• Erasmus MC RotterdamcoreStrategic or Co-development Partner · 1 January 2021Educational partnership where Erasmus MC in Rotterdam provides the theoretical portion of the radiotherapeutic technologist (radiotherapeutisch laborant) inservice HBO training program. All practical experience is gained at Verbeeten locations in Tilburg, Breda, and Den Bosch.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Maastro Clinic: Regional Dutch radiotherapy clinic with multiple locations (Maastricht, Venlo, Eindhoven, Weert) offering external beam, brachytherapy, and proton therapy referrals. Most direct structural peer: similar specialist foundation model, comparable scale, and overlapping Brabant-adjacent catchment.
• Radiotherapiegroep Arnhem / RISO: Independent radiotherapy institute with multiple locations in eastern and central Netherlands. Closely comparable operating model: regional foundation, multiple sites, focus on external beam and brachytherapy.
• Holland Proton Therapy Centre (HollandPTC): Dutch proton therapy center in Delft affiliated with Erasmus MC, LUMC, and TU Delft. Peer in advanced radiation technology deployment and academic-clinical integration, though differentiated by modality (protons vs photons).

Broad incumbents

• Radboud UMC Radiotherapy Department: University hospital radiotherapy unit in Nijmegen. Research partner with Verbeeten on surface scanning studies; serves overlapping patient populations in eastern Brabant/Gelderland with a broader academic hospital portfolio.
• UMC Utrecht, Division of Imaging and Oncology: Academic division offering image-guided radiotherapy and oncology research. Comparable advanced technology footprint; supervisory board member Jeroen Hendrikse is chair here, evidencing strong institutional ties.
• Erasmus MC Cancer Institute: Academic cancer center providing radiotherapy within a full university hospital. Verbeeten's training partner for radiotherapeutic technologists and a regional referral source for complex cases; broader portfolio including surgery and medical oncology.
• Netherlands Cancer Institute (NKI): Comprehensive cancer center in Amsterdam combining research, radiotherapy, and systemic therapy. Comparable in core radiotherapy competency but broader in scope, research intensity, and academic mission; serves as a national referral center.

Others

• Varian Medical Systems (Siemens Healthineers): OEM supplier of Verbeeten's Ethos, HyperArc, HyperSight, and Identify systems. Strategic technology partner rather than competitor; defines Verbeeten's capability envelope and roadmap cadence.

Regional players

• Catharina Hospital (Catharina Radiotherapy): Top clinical hospital in Eindhoven with in-house radiotherapy offering. Regional peer in the broader Brabant oncology ecosystem; competes for some referrals and partners with Verbeeten on complex cases.
• Belgian Hospital Radiation Oncology Centers (e.g., UZ Leuven Radiotherapy): Academic radiotherapy programs just across the Dutch border. Comparable clinical depth and technology adoption; relevant for benchmarking patient pathways and referral leakage in the southern Netherlands.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/instituut-verbeeten
• Xx.com/InstitVerbeeten
• Facebookfacebook.com/InstituutVerbeeten

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Instituut Verbeeten